VITA 34 AG: VITA 34 presents figures for the 1st half-year 2012

VITA 34 AG  / Key word(s): Half Year Results

19.07.2012 08:33

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


VITA 34 AG: VITA 34 presents figures for the 1st half-year 2012

  - Revenue and storages in period under review below last year's level
  - Increase in operating result in 1st half-year 2012
  - Conclusion of cooperation in Mexico and development of further markets

Leipzig, 19 July 2012 - VITA 34 AG (ISIN DE000A0BL849), the oldest private
umbilical cord blood bank in the German-speaking countries, has registered
a restrained business development in the first six months of 2012. While
the operating result could be increased, the number of storages and the
revenue remained below the previous year's values. The central key figure -
the earnings before interest, taxes, depreciation, and amortisation
(EBITDA) - was increased to 27,000 Euro from the negative amount of 160,000
Euro last year. The earnings before interest and taxes (EBIT) have slightly
increased from EUR -0.63 million to EUR -0.48 million. The number of
storages of umbilical cord blood preparations reduced from 4,477 one year
ago to 3,718 due to a downward trend on the core markets Germany and Spain.
The revenue amounted to approximately EUR 6.6 million compared to
approximately EUR 7.8 million in the first half-year of 2011. The group
result of approximately EUR -0.4 million was still negative and thus on the
level of the same period of last year.

We have already initiated measures to reach a positive business development
in the future and to improve the profitability, including the reduction of
expenses and the expansion of international business. A cooperation
agreement in Mexico has already been concluded. VITA 34 supports the
company CryoLifeCells in setting up its own umbilical cord blood bank in
Mexico and provides the necessary know-how and the patented decentralized
collection system for this purpose.

VITA 34 wants to further concentrate on the international activities and
thus develop new markets during the business year 2012. The corporation
already negotiates with potential partners, among others in Chile. The
cooperations in Serbia and Mexico as well as the acquisition of the
BioPlanta GmbH also should have a positive effect on the business of VITA
34. It is furthermore intended to continue reducing expenses in the course
of the year.

From today's perspective, it is clear that, due to the regression of
storages in Spain and in Germany, the sales target that has been forecast
so far for this business year cannot be reached anymore, so that a revenue
below the previous year's value has to be expected. As regards the total
year 2012, the increasingly ambitious goal is to moderately improve the
operating result (EBITDA) compared to the previous year.

The complete mid-year report including an updated forecast will be
published on 19 July 2012 and available for download at

Press/Investor Relations:

Axel Mühlhaus
Peggy Kropmanns
edicto GmbH
Eschersheimer Landstr. 42-44
D-60322 Frankfurt

Phone: +49 (069) 90550550
Fax: +49 (069) 90550577

19.07.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and

Language:     English
Company:      VITA 34 AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement                             DGAP News-Service